Influence of Socio-Demographic Factors in Patients With Cutaneous Lupus Erythematosus.
autoimmunity
cutaneous lupus
health equity
race
socio-demographic factors
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
04
2022
accepted:
16
05
2022
entrez:
28
7
2022
pubmed:
29
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
Cutaneous lupus erythematosus (CLE) is a chronic autoimmune skin disease with potential for systemic involvement, disfigurement, and significant disease burden. The relationships of demographics and socioeconomic status with patients with CLE are emerging topics with important clinical implications. The primary objective of our study is to perform a literature review of studies that have investigated demographic and socioeconomic factors amongst patients with CLE and determine whether these factors influence diagnosis frequency, disease severity and outcomes or health related quality of life. We searched multiple databases to identify literature addressing CLE and concepts such as race, ethnicity, gender, income, education level and geographic location. Information regarding primary research objective was extracted from all full text articles, and a summary of findings was prepared. We found that race and ethnicity can influence CLE diagnosis frequency and disease outcomes. Chronic cutaneous lupus (CCLE) occurs more frequently in Black patients, often with higher overall disease damage. Differences between genders exist in CLE in terms of health-related quality of life, as female gender was a risk factor for worse quality of life in several studies. Lower income, low educational attainment, and lack of health insurance all contribute to poorer overall outcomes in CLE patients. This review will help inform physicians about populations at risk for potentially worse outcomes to guide treatment decisions for patients with CLE and provide important information to design interventions that address modifiable social determinants of health in this population.
Identifiants
pubmed: 35899206
doi: 10.3389/fmed.2022.916134
pmc: PMC9311297
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
916134Informations de copyright
Copyright © 2022 Walker, Lu, Clifton, Ogunsanya and Chong.
Déclaration de conflit d'intérêts
BC is an investigator for Daavlin Corporation and Biogen Incorporated and Pfizer Incorporated. He is a consultant for Bristol Meyers Squibb, EMD Serono, Horizon Therapeutics, and Biogen Incorporated. He receives royalties from MAPI Research Trust. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Dermatol. 2022 Jan 4;:
pubmed: 34982837
J Am Acad Dermatol. 2022 Feb 7;:
pubmed: 35143915
Arthritis Care Res (Hoboken). 2015 May;67(6):817-28
pubmed: 25369985
Lupus Sci Med. 2021 Nov;8(1):
pubmed: 34853149
Expert Rev Clin Immunol. 2017 Aug;13(8):799-814
pubmed: 28471259
Chronic Illn. 2021 Mar;17(1):53-66
pubmed: 30782011
Arthritis Care Res (Hoboken). 2019 Dec;71(12):1647-1652
pubmed: 29693320
Br J Dermatol. 2013 Jan;168(1):145-53
pubmed: 22708924
Lupus Sci Med. 2019 Oct 30;6(1):e000344
pubmed: 31798917
Br J Dermatol. 2012 Feb;166(2):372-9
pubmed: 21966891
Lupus. 2016 Nov;25(13):1497-1502
pubmed: 27235700
Arthritis Care Res (Hoboken). 2012 May;64(5):704-12
pubmed: 22190480
Br J Dermatol. 2008 Aug;159(2):351-9
pubmed: 18565189
Am J Clin Dermatol. 2019 Jun;20(3):465-475
pubmed: 30877492
JAMA Dermatol. 2018 Jun 1;154(6):712-716
pubmed: 29801110
J Am Acad Dermatol. 1981 Apr;4(4):471-5
pubmed: 7229150
Arthritis Rheum. 2013 Mar;65(3):753-63
pubmed: 23203603
J Eur Acad Dermatol Venereol. 2007 Feb;21(2):219-26
pubmed: 17243958
Lupus Sci Med. 2020 Jan 27;7(1):e000364
pubmed: 32095249
Br J Dermatol. 2018 Nov;179(5):1095-1101
pubmed: 29885269
Br J Dermatol. 2017 Oct;177(4):e147-e149
pubmed: 28338221
Int J Womens Dermatol. 2021 Jul 31;7(5Part B):743-746
pubmed: 35028375
Br J Dermatol. 2021 Sep;185(3):563-572
pubmed: 33400293
J Am Acad Dermatol. 2022 Feb 7;:
pubmed: 35143914
Arthritis Care Res (Hoboken). 2010 Feb;62(2):279-82
pubmed: 20191529
Front Immunol. 2022 Mar 11;13:866319
pubmed: 35359921
Lupus. 2021 May;30(6):972-980
pubmed: 33663251
Lupus. 2018 Jun;27(7):1107-1115
pubmed: 29514557
Arthritis Care Res (Hoboken). 2019 Jan;71(1):95-103
pubmed: 29669194
Br J Dermatol. 2014 Feb;170(2):315-21
pubmed: 24111880
Australas J Dermatol. 2020 Aug;61(3):291-292
pubmed: 32255506
J Am Acad Dermatol. 2018 Dec;79(6):1053-1060.e3
pubmed: 29969701
Arch Dermatol. 2009 Mar;145(3):249-53
pubmed: 19289752
J Am Acad Dermatol. 2011 May;64(5):849-58
pubmed: 21397983
Health Promot Int. 2019 Oct 1;34(5):e1-e17
pubmed: 30107564
Lupus. 2014;23(1):93-101
pubmed: 24197553
Rheumatology (Oxford). 2020 Dec 5;59(Suppl5):v29-v38
pubmed: 33280012